“Improving Trauma and Burn patient care: The clinical relevance of omics based research”

06 December 2017

Prof Ronald Tompkins (Harvard Medical School, Boston)

Improving Trauma and Burn patient care: The clinical relevance of omics based research

Wednesday 6th December 2017

5:00 – 6:30pm

Leonard Deacon Lecture Theatre, College of Medical and Dental Sciences, University of Birmingham


Ronald G. Tompkins, MD, ScD, is the Sumner M. Redstone Professor of Surgery at Harvard Medical School, Founding Director of the Centre for Surgery, Science & Bioengineering at Massachusetts General Hospital, and Chief of Staff Emeritus at Shriners Hospitals for Children―Boston. Ron Tompkins is a board-certified general surgeon with a doctorate in chemical engineering, which provides him with expertise not only in the clinical evaluation of critical care patients, but also in inflammation biology, genomics, proteomics, and computational biology.

Elected as a Director of the American Board of Surgery in 1994, he has received multiple honours including a fellowship from the American Institute for Medical and Biological Engineering and an honorary M.A. from Harvard University. He has served as an officer including as President and Board Member of more than a dozen national and international academic societies. He has published more than 450 research papers in medicine and engineering journals and has contributed to the advancement of science and engineering through service on institutional advisory panels, moderating mini-symposia and workshops on biotechnology, and studying the genomics and proteomics of immunology and metabolism resulting from injury.

Dr Tompkins serves as the principal investigator of the first-in-the-nation P50 award (P50-GM21700 in 1974) from the National Institute of General Medical Sciences and its associated NIGMS T32 Burn Research Training Grant (T32-GM07035 in 1975) for postdoctoral training in burn and trauma research. His research as the principal investigator of the “Inflammation and the Host Response to Injury” program (U54-GM062119) — the largest award ever received by MGH and 10th largest of the extramural NIH grants — has developed the clinical infrastructure to study critically ill trauma populations, as well as the technological and bioinformatics skills to isolate leukocyte populations and probe the transcriptome as it responds to severe injury. The development of clinical treatment protocols by consensus of the trauma and burn centres participating in this “Glue Grant” program led to improvements in survival, reduction in morbidity for injured patients, and established benchmarks for care in the fields of burns and trauma.